Write in a clean editor, then format for Expert Review of Pharmacoeconomics & Outcomes Research in one click — DocuGuru applies the official Taylor & Francis template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Expert Review of Pharmacoeconomics & Outcomes Research is a peer-reviewed journal published by Taylor & Francis, covering Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Economic and Financial Impacts of Cancer.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Numbered (Vancouver/NLM) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;12(3):45–58.
Formats any DOI in Expert Review of Pharmacoeconomics & Outcomes Research style. No sign-up. |
| Publishes research in | Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Economic and Financial Impacts of Cancer Healthcare Policy and Management Global Health Care Issues |
| ISSN | 1473-7167 |
| Citation impact (2-yr) | 1.79 |
| h-index | 81 |
| i10-index | 832 |
| Total citations | 38,213 |
| Top institutions publishing here | Karolinska Institutet |
| Journal website | informahealthcare.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
This study describes the development and reports the first psychometric results of the European KIDSCREEN-52 generic health-related quality-of-life questionnaire for children and adolescents. The KIDSCREEN-52, including ten dimensions, was applied in a European survey involving 12 countries (i.e., Austria, Switzerland, Czech Republic, Germany, Greece, Spain, France, Hungary, The Netherlands, Poland, Sweden and the UK) and…
The minimal important difference (MID) is a phrase with instant appeal in a field struggling to interpret health-related quality of life and other patient-reported outcomes. The terminology can be confusing, with several terms differing only slightly in definition (e.g., minimal clinically important difference, clinically important difference, minimally detectable difference, the subjectively significant difference), and others…
Cost-effectiveness analyses, particularly in the USA, commonly use a figure of $50,000 per life-year or quality-adjusted life-year gained as a threshold for assessing the cost-effectiveness of an intervention. The history of this practice is ill defined, although it has been linked to the end-stage renal disease kidney dialysis cost-effectiveness literature from the 1980s. The use…
In the patient-reported outcomes (PROs) field, strict regulatory requirements must be met for qualitative research that contributes to labeling claims for medicinal products. These requirements not only emphasize the importance of reaching saturation but also of providing documentary evidence that saturation has been reached. This paper reviews qualitative literature for useful definitions of the concept…
In this issue of Expert Review of Pharmacoeconomics and Outcomes Research, Farivar, Liu, and Hays present their findings in 'Another look at the half standard deviation estimate of the minimally important difference in health-related quality of life scores (hereafter referred to as 'Another look') . These researchers have re-examined the May 2003 Medical Care article…
